Moderna’s Cancer Vaccine Breakthrough | Phoenix News

Moderna just dropped a game-changing bombshell: their new personalized mRNA cancer vaccine, tested alongside Merck’s Keytruda, slashed melanoma recurrence in a landmark late-stage trial—marking the first time an mRNA vaccine has proven effective against solid tumors. By training the immune system to target unique cancer mutations, the combo therapy outperformed Keytruda alone, opening the door for similar vaccines in lung, breast, and pancreatic cancers. Experts are calling it the dawn of a new era in cancer treatment. The news sent Moderna’s stock soaring, boosting Merck too, as both companies gear up for potential approval next year—offering renewed hope for thousands of melanoma survivors. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a432c727261ef59b